Melasma
Conditions
Interventions
Experimental group: picosecond Nd:YAG laser treatment
Control group: picosecond Alexandrite laser treatment
Sponsors
Hospital for Skin Disease (Institute of Dermatology), Chinese Academy of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with clinical or pathological diagnosis of chloasma. 2. Healthy male / female aged from 18 to 60 years. 3. Fitzpatrick skin type III - V patients. 4. The subject or guardian can understand and provide written informed consent, and is able and willing to comply with all the time and requirements of interview, treatment and evaluation, including photo shooting that may be used for publishing and reporting. 5. Women of childbearing age are required to use reliable contraceptive methods at least 3 months before the start of study recruitment.
Exclusion criteria
Exclusion criteria: 1. Lactating women. 2. The patient's sensitivity to infrared wavelength 2. 3. Patients who have taken drugs to improve photosensitivity. 4. Patients with epilepsy caused by light. 5. Patients who used oral isotretinoin within 6 weeks before treatment or during the study. 6. Patients who had taken tranexamic acid orally within one year before treatment. 7. Patients who had received facial laser treatment before treatment. 8. Patients with active local or systemic infection, or open wounds in the treatment area. 9. Patients with previous history of keloid formation or poor wound healing in the area of skin injury. 10. Patients with cutaneous lupus erythematosus. 11. Patients with active herpes simplex in the treatment area. 12. Patients with multiple dysplastic nevi in the treatment area. 13. Patients with any form of active malignancy during recruitment or study. 14. Patients with obvious systemic diseases or obvious diseases in the treatment area. 15. Patients who participated in the study of other devices or drugs within one month before the start of treatment or during the study. 16. Any situation in which treatment of a subject as part of the study, in the opinion of the investigator, may be unsafe (for the subject or researcher).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melasma area severity index, MASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| investigator's global assessment, IGA);Global aesthetic improvement scale, GAIS; Pain viasual analogue scale;efficiency rate;cure rate; | — |
Countries
China
Contacts
Public ContactTong Lin
Hospital for Skin Disease(Institute of Dermatology),Chinese Academy of Medical Science
Outcome results
None listed